The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years

Journal of Bone and Mineral Research

Volumn 27, Issue 12, 2012, Pages 2429-2437

  Andrews, Elizabeth B ^a   Gilsenan, Alicia W ^a   Midkiff, Kirk ^a   Sherrill, Beth ^a   Wu, Yun ^a   Mann, Beth H ^b   Masica, Daniel ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

EPIDEMIOLOGY; OSTEOSARCOMA; PARATHYROID HORMONE (PTH); SURVEILLANCE; TERIPARATIDE

Indexed keywords

PARATHYROID HORMONE[1-34];

ADULT; AGED; ARTICLE; BONE TUMOR; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OSTEOSARCOMA; POSTMARKETING SURVEILLANCE; RISK FACTOR; TELECONSULTATION; UNITED STATES;

EID: 84869413759     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1768     Document Type: Article

References (19)

1. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB., Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002 May-Jun; 30 (3): 312-21.
2. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M., Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004 Jul-Aug; 32 (4): 426-38.
3. Vahle JL, Zuehlke U, Schmidt A, Westmore M, Chen P, Sato M., Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res. 2008 Dec; 23 (12): 2033-9.
4. Mirabello L, Troisi RJ, Savage SA., International osteosarcoma incidence patterns in children and adolescents. m iddle ages and elderly persons. Int J Cancer. 2009 Jul 1; 125 (1): 229-34.
5. Mirabello L, Troisi RJ, Savage SA., Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009 Apr 1; 115 (7): 1531-43.
6. Grimer RJ, Cannon SR, Taminiau AM, Bielack S, Kempf-Bielack B, Windhager R, Dominkus M, Saeter G, Bauer H, Meller I, Szendroi M, Folleras G, San-Julian M, van der Eijken J., Osteosarcoma over the age of forty. Eur J Cancer. 2003 Jan; 39 (2): 157-63.
7. Unni KK, Dahlin DC., Dahlin's bone tumor: general aspects and data on 11,087 cases. 5th ed. Philadelphia: Lippincott-Raven; 1996. p. 67-69, 143-4.
8. Savage SA, Mirabello L., Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011; 2011: 548151.
9. Merletti F, Richiardi L, Bertoni F, Ahrens W, Buemi A, Costa-Santos C, Eriksson M, Guénel P, Kaerlev L, Jöckel KH, Llopis-Gonzalez A, Merler E, Miranda A, Morales-Suárez-Varela MM, Olsson H, Fletcher T, Olsen J., Occupational factors and risk of adult bone sarcomas: a multicentric case-control study in Europe. Int J Cancer. 2006 Feb 1; 118 (3): 721-7.
10. Kim FM, Hayes C, Williams PL, Whitford GM, Joshipura KJ, Hoover RN, Douglass CW., National Osteosarcoma Etiology Group. An assessment of bone fluoride and osteosarcoma. J Dent Res. 2011 Oct; 90 (10): 1171-6.
11. National Cancer Institute (US). Fluoridated water fact sheet [Internet]. Bethesda, MD: National Cancer Institute [reviewed 21 Feb 2012; cited 2011 Dec 2]. Available from: http://www.cancer.gov/cancertopics/factsheet/Risk/ fluoridated-water.
12. von Schéele B, Martin RD, Gilsenan AW, Ceberg J, Andrews EB, Masica D, AlvegÃ¥rd T., The European postmarketing adult osteosarcoma surveillance study: characteristics of patients. Acta Orthopaedica. 2009; 80 (Suppl 334): 67-74.
13. Centers for Disease Control and Prevention (US). National Program of Cancer Registries (NPCR) [Internet]. Atlanta, GA: Centers for Disease Control and Prevention [updated 2011 Oct 11; cited 2011 Nov 5]. Available from: http://www.cdc.gov/cancer/npcr/about.htm.
14. Harper KD, Krege JH, Marcus R, Mitlak BH., Osteosarcoma and teriparatide?. J Bone Miner Res. 2007 Feb; 22 (2): 334.
15. Lubitz R, Prasad S., Case report: osteosarcoma and teriparatide (abstract). Poster presented at the ASBMR 31st Annual Meeting. J Bone Miner Res. 2009; 24 (Suppl 1): SU0354.
16. Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA., Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int. 2010 Jun; 21 (6): 1041-5.
17. Software: Surveillance Research Program, National Cancer Institute SEER Stat software (www.seer.cancer.gov/seerstat) version 7.1.0. Data: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER Stat Database: Incidence-SEER 18 Regs Research Data+Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973-2009varying)-Linked to County Attributes-Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission.
18. Groves RM, Fowler FJ Jr, Couper MP, Lepkowski JM., Nonresponse in sample surveys. In: Survey methodology. 2nd ed. Hoboken, NJ: John Wiley and Sons; p. 183-211. 2009.
19. Department of Health and Human Services (US). Standards for privacy of individually identifiable health information. Final rule. Fed Regist. 2002 Aug 14; 67 (157): 53181-273.